IP Verse

Methods Of Treating Ovarian Cancer

Patent No. EP3478286 (titled "Methods Of Treating Ovarian Cancer") was filed by Tesaro on Jun 29, 2017. The application was issued on Jan 3, 2024.

Patent Summary

Anti-PARP therapy to improve the prognosis of ovarian cancer. The therapy includes administering niraparib, a pharmaceutically acceptable salt thereof for use in treating cancer patients exhibiting an absence of a germline mutation in BRCA1 or BRCA2, or a reduction hazard ratio for disease progression or death as compared to control, a reduced hazard ratio for disease progression or death as compared to control, iii) prolonged overall survival as compared to control, or iv) an overall response rate of at least 30%.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKOct 3, 2024RUSSELL
ALFRED E TIEFENBACHEROct 2, 2024HAMM & WITTKOPP
STADA ARZNEIMITTELOct 2, 2024HAMM & WITTKOPP
STRAWMANOct 2, 2024BRAND MURRAY FULLER
KRAUS & LEDERER PARTGMBBOct 1, 2024KRAUS & LEDERER PARTGMBB
TEVA PHARMACEUTICALSOct 1, 2024D YOUNG
SANDOZSep 18, 2024ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3478286

TESARO
Application Number
EP17821262A
Filing Date
Jun 29, 2017
Status
Granted And Under Opposition
Dec 1, 2023
Publication Date
Jan 3, 2024
External Links
Slate, Register , Google Patents